Showing results (81-90 of 182) with videos related to
Sort By:
Pageof 19
Seminars in Urologic Oncology|November 1, 1996
Renal cell carcinoma: basic biology and clinical behaviorJ R Franklin, R Figlin, A BelldegrunReviews in Urology|September 21, 2006
Immune and genetic therapies for advanced renal cell carcinomaA Zisman, A J Pantuck, A BelldegrunThe Prostate|August 10, 1999
Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: independence of de novo protein synthesisP J Frost, A Belldegrun, B BonavidaCancer Research|January 1, 1988
Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activityA Belldegrun, L M Muul, S A RosenbergSeminars in Urologic Oncology|November 1, 1996
Immunotherapy and gene therapyB J Gitlitz, A Belldegrun, R A FiglinSeminars in Urology|February 1, 1992
Immunotherapy for renal cell carcinomaA Belldegrun, R Figlin, J Danella, et al.Cellular Immunology|August 25, 1997
Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicityP Frost, C P Ng, A Belldegrun, et al.The Journal of Urology|June 1, 1981
Results of inferior vena cava resection for renal cell carcinomaG P Kearney, W B Waters, L A Klein, et al.Microsurgery|January 1, 1990
Arterialization of the liver. III. Influence of systemic and portal pressure gradients following heterotopic partial liver transplantationM D'Silva, J Pirenne, E Glassford, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1990
Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluidA Belldegrun, A Kasid, M Uppenkamp, et al.Pageof 19